Thirty-seven million people living with HIV worldwide, including 1.8 million children.
Eighteen million new cancer cases in 2018 with over 9.5 million deaths worldwide.
Six thousand genetic disorders, many of which are fatal or debilitating.
The price for a one-time advanced therapy is $350,000+, not including hospital costs.
These are some of the statistics that demonstrate why cures are needed and why it is important to develop impact strategies, so cures become affordable and accessible to all in need around the world. These pages highlight some of our cure candidate projects.
As the technology that enables new curative approaches to disease evolves, it is important that these specific interventions are developed and manufactured affordably so they become accessible to all in need.
We develop curative medicinal candidates for specific diseases and support cure research and development with our collaborators and partners.
Here’s how we do this:
- Conducting, collaborating, and supporting basic research
- Developing curative medicinal candidates at our laboratories and with our collaborating partners
- Conducting and facilitating pre-clinical studies to prepare curative medicinal candidates for clinical testing
- Collaborating with our network of clinical centers to establish safety and efficacy of curative medicinal candidates in clinical trials
- Working with our partners to facilitate distributive or place-of-care manufacturing of approved autologous gene-modified cell products at hospitals
- Conducting and supporting pivotal clinical trials and regulatory approval of curative medicinal candidates
- Enabling innovation and implementation of technologies that are important for affordable manufacture and distribution of advanced medicinal cures